Show simple item record

dc.contributor.authorMarr, L A
dc.contributor.authorGilham, David E
dc.contributor.authorCampbell, J D M
dc.contributor.authorFraser, A R
dc.date.accessioned2012-03-22T13:18:38Z
dc.date.available2012-03-22T13:18:38Z
dc.date.issued2012-02
dc.identifier.citationImmunology in the clinic review series; focus on cancer: double trouble for tumours: bi-functional and redirected T cells as effective cancer immunotherapies. 2012, 167 (2):216-25 Clin Exp Immunolen_GB
dc.identifier.issn1365-2249
dc.identifier.pmid22235997
dc.identifier.doi10.1111/j.1365-2249.2011.04517.x
dc.identifier.urihttp://hdl.handle.net/10541/216291
dc.description.abstractCancer is one of the most important pathological conditions facing mankind in the 21st century, and is likely to become the most important cause of death as improvements continue in health, diet and life expectancy. The immune response is responsible for controlling nascent cancer through immunosurveillance. If tumours escape this control, they can develop into clinical cancer. Although surgery and chemo- or radiotherapy have improved survival rates significantly, there is a drive to reharness immune responses to treat disease. As T cells are one of the key immune cells in controlling cancer, research is under way to enhance their function and improve tumour targeting. This can be achieved by transduction with tumour-specific T cell receptor (TCR) or chimaeric antigen receptors (CAR) to generate redirected T cells. Virus-specific cells can also be transduced with TCR or CAR to create bi-functional T cells with specificity for both virus and tumour. In this review we outline the development and optimization of redirected and bi-functional T cells, and outline the results from current clinical trials using these cells. From this we discuss the challenges involved in generating effective anti-tumour responses while avoiding concomitant damage to normal tissues and organs.
dc.language.isoenen
dc.rightsArchived with thanks to Clinical and experimental immunologyen_GB
dc.subject.meshAnimals
dc.subject.meshAntigens, Neoplasm
dc.subject.meshClinical Trials as Topic
dc.subject.meshGenetic Vectors
dc.subject.meshHumans
dc.subject.meshImmunologic Surveillance
dc.subject.meshImmunotherapy
dc.subject.meshImmunotherapy, Adoptive
dc.subject.meshMice
dc.subject.meshMolecular Targeted Therapy
dc.subject.meshNeoplasms
dc.subject.meshReceptors, Antigen, T-Cell
dc.subject.meshRecombinant Fusion Proteins
dc.subject.meshT-Cell Antigen Receptor Specificity
dc.subject.meshT-Lymphocyte Subsets
dc.subject.meshTransduction, Genetic
dc.subject.meshTransplantation Conditioning
dc.subject.meshTumor Escape
dc.subject.meshTumor Microenvironment
dc.titleImmunology in the clinic review series; focus on cancer: double trouble for tumours: bi-functional and redirected T cells as effective cancer immunotherapies.en
dc.typeArticleen
dc.contributor.departmentChemokine Research Group, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.en_GB
dc.identifier.journalClinical and Experimental Immunologyen_GB
html.description.abstractCancer is one of the most important pathological conditions facing mankind in the 21st century, and is likely to become the most important cause of death as improvements continue in health, diet and life expectancy. The immune response is responsible for controlling nascent cancer through immunosurveillance. If tumours escape this control, they can develop into clinical cancer. Although surgery and chemo- or radiotherapy have improved survival rates significantly, there is a drive to reharness immune responses to treat disease. As T cells are one of the key immune cells in controlling cancer, research is under way to enhance their function and improve tumour targeting. This can be achieved by transduction with tumour-specific T cell receptor (TCR) or chimaeric antigen receptors (CAR) to generate redirected T cells. Virus-specific cells can also be transduced with TCR or CAR to create bi-functional T cells with specificity for both virus and tumour. In this review we outline the development and optimization of redirected and bi-functional T cells, and outline the results from current clinical trials using these cells. From this we discuss the challenges involved in generating effective anti-tumour responses while avoiding concomitant damage to normal tissues and organs.


This item appears in the following Collection(s)

Show simple item record